EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Angiotensin-Converting Enzyme and Heart Failure

Sara Álvarez-Zaballos, Manuel Martínez-Sellés

Frontiers in Bioscience-Landmark · 2023

DOI: 10.31083/j.fbl2807150 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, 2023. Verfasst von Sara Álvarez-Zaballos und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Hospital General Universitario Gregorio Marañón, CIBERCV, 28007 Madrid, Spain. Hauptthemen laut MEDLINE: Heart Failure, Angiotensin-Converting Enzyme Inhibitors, Peptidyl-Dipeptidase A. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacotherapy is the cornerstone treatment for patients with heart failure (HF) that uses drugs targeting the renin-angiotensin-aldosterone system (RAAS), including angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan. This article reviews the pathophysiology of the RAAS and the neurohormonal changes seen in patients with HF as well as the targets and the mode of action of these drugs. We also assess the role of ACE in ventricular remodeling and summarize the main evidence for the use of ACE-related drugs in HF patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureAngiotensin-Converting Enzyme InhibitorsPeptidyl-Dipeptidase AHumansRenin-Angiotensin SystemAngiotensin Receptor AntagonistsAminobutyratesBiphenyl CompoundsTetrazolesVentricular RemodelingValsartanDrug CombinationsNeprilysin

Stichwörter der Autor:innen

angiotensin-converting enzymeheart failuremortality

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsPeptidyl-Dipeptidase AAminobutyratesBiphenyl CompoundsTetrazolessacubitril and valsartan sodium hydrate drug combinationValsartanDrug CombinationsNeprilysin

Autor:innen und Institutionen

  • Cardiology Department, Hospital General Universitario Gregorio Marañón, CIBERCV, 28007 Madrid, Spain.
  • School of Health and Biomedical Sciences, Universidad Europea, 28670 Madrid, Spain.
  • School of Medicine, Universidad Complutense, 28040 Madrid, Spain.

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Álvarez-Zaballos, S., & Martínez-Sellés, M. (2023). Angiotensin-Converting Enzyme and Heart Failure. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2807150

Vancouver

Álvarez-Zaballos S, Martínez-Sellés M. Angiotensin-Converting Enzyme and Heart Failure. Frontiers in Bioscience-Landmark. 2023. doi:10.31083/j.fbl2807150

BibTeX
@article{lvarezZaballos2023,
  author = {Álvarez-Zaballos, Sara and Martínez-Sellés, Manuel},
  title = {Angiotensin-Converting Enzyme and Heart Failure},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2023},
  doi = {10.31083/j.fbl2807150}
}
Kostenlos starten →